Cutler Group LP Prothena Corp Public LTD CO Call Options Transaction History

Cutler Group LP

11 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2023 Jan 18, 2024	BUY	$32.31 - $52.32 $458,802 - $742,944	14,200 New	14,200 $132,000
Q4 2022 Feb 07, 2023	SELL	$52.05 - $65.0 $218,610 - $273,000	-4,200 Reduced 97.67%	100 $0
Q3 2022 Oct 25, 2022	BUY	$25.16 - $60.63 $108,188 - $260,709	4,300 New	4,300 $44,000
Q4 2021 Jan 18, 2022	SELL	$42.11 - $73.26 $315,825 - $549,450	-7,500 Closed	0 $0
Q3 2021 Oct 26, 2021	SELL	$48.2 - $78.89 $43,380 - $71,001	-900 Reduced 10.71%	7,500 $41,000
Q2 2021 Jul 19, 2021	BUY	$21.63 - $57.65 $181,692 - $484,260	8,400 New	8,400 $22,000
Q3 2020 Oct 27, 2020	SELL	$9.93 - $13.47 $1,986 - $2,694	-200 Closed	0 $0
Q1 2020 May 07, 2020	SELL	$7.54 - $15.77 $97,266 - $203,433	-12,900 Reduced 98.47%	200 $0
Q1 2018 May 11, 2018	BUY	$27.95 - $45.04 $268,320 - $432,384	9,600 Added 274.29%	13,100 $73,000
Q4 2017 Jan 17, 2018	BUY	$35.44 - $63.76 $60,247 - $108,392	1,700 Added 94.44%	3,500 $5,000
Q3 2017 Oct 17, 2017	BUY	$53.83 - $67.75 $96,894 - $121,950	1,800	1,800 $3,000

184

42.7M

162K

102K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $723M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.